Corona blog 2023

The Corona Blog 2023 is the continuation of what has become very extensive in recent years old blogs. This blog deals with background information that has become known, particularly from the pharmaceutical industry and health authority institutions at an international level.

As usual, no comments from me will be included here either. Everyone can inform themselves, research and draw their own conclusions.

Supply bottleneck of anticoagulants

Already with Letter dated August 15, 2022 Boehringer Ingelheim informed that due to the increasing number of patients requiring thrombolytic treatment, the availability of the corresponding medications, in particular Actilyse®, Actilyse® Cathflo and Metalyse®, is expected to result in a “delivery bottleneck or even a temporary interruption in delivery”.

(Source: Federal Institute for Drugs and Medical Devices bfarm.de)

With Letter dated September 23, 2022 Boehringer Ingelheim also points out that the delivery bottleneck of the drug Metalyse® 10,000 U powder and solvent for the production of an injection solution, “for thrombolytic therapy in suspected acute myocardial infarction with persistent ST segment elevation or recent left bundle branch block within 6 hours of the onset of symptoms of an acute myocardial infarction. “ is expected to last until 2024.

(Source: Federal Institute for Drugs and Medical Devices bfarm.de)